#	Pagina
attuale pagina	/open-h2020/projects/197354/index.html

Opendata, web and dolomites

MammaPrint SIGNED

Improved breast cancer care by innovative diagnostic test MammaPrint

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

MammaPrint project word cloud

Explore the words cloud of the MammaPrint project. It provides you a very rough idea of what is the project "MammaPrint" about.

fits nv accurately tests proportion outcomes commercialization surgery world netherlands human risk pursue recommend last cancers breast spin genome therapy mammaprint genomic guidelines treatment founded starting benefit tumor physicians diagnostic commom full prognosis patients molecular women microarray chemotherapy dna agendia cancer invasive identifies health adoption decisions players reimbursement profiling 2003 stage solution worldwide dutch death leads recurrence market utility surgical entire advancements appropriate introducing is sme analyzing personalized reducing size diagnostics difficult arrangements clinical off gain adjuvant

Project "MammaPrint" data sheet

The following table provides information about the project.

Coordinator	Agendia NV Organization address address: Science Park 406 city: Amsterdam postcode: 1098XH website: www.agendia.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	https://www.agendia.com/clinical-trials/horizon-2020/
Total cost	4˙048˙407 €
EC max contribution	4˙048˙407 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2014
Funding Scheme	SME-2
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2018-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	Agendia NV Agendia NV Organization address address: Science Park 406 city: Amsterdam postcode: 1098XH website: www.agendia.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Amsterdam)	coordinator	4˙048˙407.00

Map

Project objective

Agendia NV, a Dutch SME, was founded in 2003 as spin-off from the Netherlands Cancer Institute. They pursue the commercialization of molecular diagnostics using DNA microarray technology for cancer. Agendia aims to be one of the key market players in genomic breast cancer profiling. One of the products Agendia is developing is MammaPrint, a breast cancer recurrence test. This test identifies the risk of recurrence of cancer after surgical treatment, so that the appropriate adjuvant treatment can be selected personalized on the patients tumor characteristics.

Breast cancer is the most commom cancer in the world and the principle cause of death of cancer among women worldwide. Currently guidelines recommend that adjuvant therapy is to be considered for all patients with early invasive breast cancer after surgery. However this 'one size fits all approach' leads to a proportion of patients being over- or under treated as the risk of recurrence is difficult to determine. The advancements in molecular diagnostics are starting to improve the prognosis and treatment of breast- and other cancers. MammaPrint is a molecular diagnostic based on analyzing the entire human genome. Agendia’s solution therefore enables better clinical decisions, reducing over- and under-treatment and therefore leading to better health outcomes and less costs.

MammaPrint can be used for all early stage breast cancer patients, which is unique in the field of breast cancer recurrence tests. As MammaPrint will be developed for more accurately identifying which breast cancer patients will gain the most benefit of adjuvant chemotherapy, the potential market for introducing MammaPrint is worldwide. In order to reach this full scale adoption, this project is focused to achieve the last clinical evidence for the clinical utility of this test needed for the uptake in EU and US clinical guidelines and reimbursement arrangements. This uptake is necessary for adoption of MammaPrint by physicians worldwide.

Deliverables

List of deliverables.
Audit of certificates (budget)	Documents, reports	2019-07-22 08:26:45
6 peer-reviewed scientific publications and 26 presentations at (scientific) conferences	Websites, patent fillings, videos etc.	2019-06-06 16:30:57
Final research report ABCSG 8	Documents, reports	2019-06-06 16:31:03
Final research report STO High Risk trial	Documents, reports	2019-06-06 16:30:59
Final report to European Commission	Documents, reports	2019-06-06 16:30:55
Press releases and items covered by media	Websites, patent fillings, videos etc.	2019-06-06 16:30:53
Finalized data management plan	Documents, reports	2019-05-30 11:38:49
Finalized communication plan	Documents, reports	2019-05-30 11:38:49
Annual reports to European Commission	Documents, reports	2019-05-30 11:38:48
Final research report PRIMe	Documents, reports	2019-05-30 11:38:50
METC approval	Websites, patent fillings, videos etc.	2019-05-30 11:38:53

Take a look to the deliverables list in detail: detailed list of MammaPrint deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAMMAPRINT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAMMAPRINT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials